PT  - JOURNAL ARTICLE
AU  - Xuping Xie
AU  - Jing Zou
AU  - Camila R. Fontes-Garfias
AU  - Hongjie Xia
AU  - Kena A. Swanson
AU  - Mark Cutler
AU  - David Cooper
AU  - Vineet D. Menachery
AU  - Scott Weaver
AU  - Philip R. Dormitzer
AU  - Pei-Yong Shi
TI  - Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera
AID  - 10.1101/2021.01.07.425740
DP  - 2021 Jan 01
TA  - bioRxiv
PG  - 2021.01.07.425740
4099  - http://biorxiv.org/content/early/2021/01/07/2021.01.07.425740.short
4100  - http://biorxiv.org/content/early/2021/01/07/2021.01.07.425740.full
AB  - Rapidly spreading variants of SARS-CoV-2 that have arisen in the United Kingdom and South Africa share the spike N501Y substitution, which is of particular concern because it is located in the viral receptor binding site for cell entry and increases binding to the receptor (angiotensin converting enzyme 2). We generated isogenic N501 and Y501 SARS-CoV-2. Sera of 20 participants in a previously reported trial of the mRNA-based COVID-19 vaccine BNT162b2 had equivalent neutralizing titers to the N501 and Y501 viruses.Competing Interest StatementX.X., V.D.M., and P.-Y.S. have filed a patent on the reverse genetic system. K.A.S., M.C., D.C., and P.R.D. are employees of Pfizer and may hold stock options. X.P., J.Z., C.R.F.G., H.X., and P.-Y.S. received compensation from Pfizer to perform the neutralization assay.